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use#LAAGermline mutations in the BRCA1 and BRCA2 genes 
account for 5% of all breast cancers and nearly 80% of 
families with hereditary breast cancer and ovarian cancer. 
Th  ese genes preserve genomic integrity by playing 
important roles in multiple DNA damage response path-
ways, including homologous recombination repair [1]. 
BRCA1 encodes a large 1,863-amino-acid protein that 
harbors an amino-terminal RING domain and two tandem 
carboxy-terminal BRCT domains (Figure 1a). Th  e  RING 
domain functions as an E3 ubiquitin ligase by recruiting 
an E2 ubiquitin-conjugating enzyme, while the BRCT 
domains are phosphopeptide recognition modules [2,3] 
that enable BRCA1 binding to phosphorylated partners 
such as Abraxas, BACH1, and CtIP [1]. Cancer-causing 
mutations in patients occur in both the RING and BRCT 
domains.
BRCA1 is unlike most E3 ubiquitin ligases in that its 
activity is enhanced by dimerization with the RING 
domain of a second protein, BARD1. Th   e RING domains 
of BRCA1 and BARD1 form a four-helix bundle. Of note, 
the E2 enzyme makes contacts with the RING domain of 
BRCA1 but not with that of BARD1 (Figure 1b) [4]. Th  e 
mechanism by which BARD1 promotes BRCA1 ligase 
activity is therefore unclear but may involve stabilizing a 
conformation of BRCA1 optimal for E2 binding. Using 
elegant mouse models, two recent studies have examined 
the eﬀ   ect of missense RING mutations on the tumor 
suppression and DNA repair activities of BRCA1 [5,6].
Shakya and colleagues generated mice expressing 
BRCA1 with the mutation I26A [5]. Th  is mutation 
abrogates E2 binding (and thus ubiquitin-ligase activity) 
but allows assembly of the BRCA1/BARD1 heterodimer. 
Notably, the BRCA1 RING can directly bind at least eight 
E2 enzymes, all of which support mono-ubiquitination or 
poly-ubiquitination in vitro, and I26A mutation ablates 
interaction with each of these E2 enzymes [7]. Surpris-
ingly, the authors found that the I26A mutation in mice 
prevented tumor formation to the same degree as wild-
type BRCA1 in three conditional genetic models. 
Further  more, the DNA damage response remained intact 
with no changes in chromosome stability or sensitivity to 
genotoxic stress in mouse embryonic ﬁ  broblasts. In prior 
work, the authors had shown this mutation also con-
ferred no changes in homologous recombination or 
Rad51 foci formation after ionizing radiation in embry-
onic stem cells [8].
After demonstrating dispensability of E3 ligase activity 
for tumor suppression, Shakya and colleagues shifted 
their attention to the BRCT domains. Th  ey engineered 
mice with the mutation S1598F, which is known to dis-
rupt BRCT phosphopeptide binding at the analogous site 
(S1655) in human BRCA1 [9] and to cause cancer in 
patients. In contrast to I26, mutation of S1598 resulted in 
impaired homologous recombination, reduced Rad51 
foci formation after ionizing radiation, increased chromo-
some instability, and hypersensitivity to genotoxic stress 
in mouse embryonic ﬁ   broblasts. Consistent with the 
elevated genomic instability, the mice developed tumors 
at an accelerated rate in the same three genetic 
backgrounds.
In a second study, Drost and colleagues also evaluated 
the BRCA1 RING domain by generating mice with the 
distinct mutation C61G, which occurs in breast cancer 
patients [6]. Th  is mutation disrupts zinc ion binding 
necessary for stability of the RING structure. Conse-
quently, it abolishes interaction not only with E2 conju-
gating enzymes but also with BARD1 [4]. In the absence 
of p53, mice bearing the C61G mutation developed 
breast tumors at the same rate as BRCA1  null mice. 
Abstract
BRCA1 is a tumor suppressor with critical roles in 
the maintenance of genomic stability. It encodes a 
large protein with an amino-terminal RING domain 
that possesses ubiquitin-ligase activity. Given the 
occurrence of numerous cancer-causing mutations 
within its RING domain, investigators have long 
suspected that BRCA1’s ubiquitin ligase is important for 
its tumor suppression and DNA repair activities. Using 
genetically engineered mouse models, two recent 
studies shed light on this age-old hypothesis.
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examining responses to genotoxic stress, as C61G tumors 
were less sensitive to both cisplatin and the poly(ADP-
ribose) polymerase inhibitor olaparib. C61G tumors also 
acquired resistance to cisplatin, whereas BRCA1 null 
tumors remained responsive over a 250-day period. 
Because cells from C61G tumors developed more 
ionizing-radiation-induced Rad51 foci than cells from 
BRCA1 null tumors, Drost and colleagues proposed that 
hypomorphic DNA repair activity may account for the 
acquired resistance. Perhaps hypomorphic repair allows 
tumors to sustain continued damage until upregulation 
of a suppressor pathway occurs. To what extent the C61G 
mutant truly retains hypomorphic activity must be 
clariﬁ  ed, however, as homologous recombination in this 
mutant was identical to that in BRCA1 null cells [6].
Th   ese two enlightening papers provide new insight into 
function of the BRCA1 RING domain. Contrary to prior 
hypotheses, the ﬁ  rst study suggests the ubiquitin ligase 
activity of the RING domain is not essential for BRCA1’s 
roles in genomic maintenance and tumor suppression [5]. 
Conversely, structural integrity of the RING domain is 
necessary [6], and this may be related to mediation of 
tumor suppressor activity by BARD1, independent of 
BARD1’s inﬂ  uence on BRCA1 ligase function. Th  is  model 
is consistent with the ﬁ  nding  that  BARD1 null mice 
develop breast cancer [1]. Interestingly, Shakya and 
colleagues showed that ionizing-radiation-induced for-
ma  tion of conjugated ubiquitin foci (detected by the 
antibody FK2) was not aﬀ  ected by I26A mutation [5]. 
However, prior studies have demonstrated that these foci 
are abrogated by BRCA1 depletion using RNAi [10-12]. 
Is it possible that BRCA1-dependent ubiquitination at 
DNA damage foci may be due to a downstream un-
identiﬁ  ed E3 ligase? Perhaps, but we also cannot rule out 
the possibility that I26A mutation allows limited in vivo 
interaction with one of 38 E2 enzymes [13] not previously 
detected in prior, albeit very rigorous, studies of BRCA1 
binding [7,14] and that such interaction is suﬃ   cient for 
ubiquitination of some BRCA1 substrates. Examining 
whether I26A mutation aﬀ   ects DNA damage-induced 
ubiquiti  na  tion of CtIP or other BRCA1 proposed sub-
strates [1] would be informative.
A third study recently suggested that BRCA1 ubiquiti-
nates histone H2A to repress satellite DNA [15]. Th  is 
study demonstrated that I26A mutation leads to trans-
criptional derepression of satellite DNA and that addition 
of exogenous satellite RNA to cells inhibits homologous 
recombination. Reconciling these results with the normal 
homologous recombination observed in I26A mutants by 
Reid and colleagues [8] is diﬃ     cult. Despite such dis-
crepan  cies, these new studies reveal intriguing results 
about BRCA1 biology and set the stage for future work 
on this complex protein.
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